Communiqués Soleno Therapeutics, Inc.

Actions

SLNO

US8342033094

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
51,55 ^USD	+2,67%		+20,61%	+28,07%

28/06	Soleno Therapeutics soumet à la FDA une demande d'autorisation de mise sur le marché d'un nouveau médicament pour le traitement du syndrome de Prader-Willi	MT
28/06	Soleno Therapeutics, Inc. annonce le dépôt d'une demande d'autorisation de mise sur le marché auprès de la FDA américaine pour le DCCR (Diazoxide Choline) en comprimés à libération prolongée pour le traitement du syndrome de Prader-Willi	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome	28/06	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	24/06	AQ
Soleno Therapeutics : June 2024 Corporate Presentation	05/06	PU
Soleno Therapeutics Set to Join Russell 3000® Index	04/06	AQ
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024	22/05	AQ
Soleno Therapeutics to Participate in Upcoming Investor Conferences	22/05	AQ
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community	15/05	AQ
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	09/05	AQ
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock	03/05	AQ
Soleno Therapeutics Announces Proposed Public Offering of Common Stock	02/05	AQ
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome	30/04	AQ
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)	29/04	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - April 19, 2024	22/04	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19/04	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/03	AQ
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	06/03	AQ
Soleno Therapeutics : March 2024 Corporate Presentation	04/03	PU
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	22/02	AQ
Soleno Therapeutics to Present at Upcoming February Investor Conferences	01/02	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Soleno Therapeutics, Inc.

Actions

SLNO

US8342033094

Communiqués

Filtres